Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

21 results about "VASCULAR ABNORMALITY" patented technology

“Vascular anomalies are congenital abnormalities of the vascular or lymphatic system. They are benign lesions that present anywhere on the body in the form of vascular birthmarks or masses.

Cerebrovascular abnormality analysis method based on transcranial Doppler ultrasound image

The invention discloses a cerebral vessel anomaly analysis method based on a transcranial Doppler ultrasound image, which comprises the steps of TCD image data acquisition, TCD image space-time filtering preprocessing, automatic blood vessel positioning and three-dimensional modeling, the method comprises the steps of generating a standardized blood vessel segmentation model and a static blood vessel network graph, extracting blood flow quantitative parameters and spectrum qualitative features, analyzing multi-blood vessel space correlation features through a graph attention network, performing primary classification on blood flow states, performing secondary classification on lesion types, making risk grading judgment, generating intervention suggestions and outputting a structured report. By setting an automatic parameter measurement method, the manual operation time of doctors is shortened, and the speed and accuracy of lesion judgment are improved through automatic standardization judgment of frequency spectrum forms and association of multi-dimensional parameters. Meanwhile, the experience requirement of doctors for judging the lesion is reduced, and reference is conveniently provided for batch screening of primary hospitals.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Intestinal tumor risk assessment method based on image analysis

The invention relates to the technical field of tumor risk assessment, in particular to an intestinal tumor risk assessment method based on image analysis, and the method comprises the steps: carrying out the continuous image division and parameter collection; identifying abnormal density image blocks; identifying concerned risk image blocks; judging a response risk image block; adjusting a preset synchronization degree risk threshold value; early warning judgment is carried out, and a serious early warning report is generated. According to the method, a self-adaptive and dynamically-adjusted three-level judgment system is established through real-time collaborative analysis of multi-dimensional parameters of an enteroscope image block, firstly, a suspected focus is locked based on the texture change duration, then, the focus characteristics are verified through vascular abnormality and contrast fluctuation depth, and finally, the accuracy of the focus is improved. And finally, the risk threshold is corrected in combination with intestinal wall peristalsis and the lens shielding degree, so that the problem of low early flat tumor recognition accuracy caused by insufficient flat tumor image feature capture due to excessive dependence on intestinal environment microorganism and metabolite biochemical detection is effectively solved.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Ecobiotic composition capable of preventing and treating redness, signs of skin aging and vascular abnormalities

The present invention relates to a cosmetic composition, advantageously an eco-biological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the general formula (I) in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an alpha-amino acid chosen from the group consisting of phenylalanine, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The present invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating cutaneous vascular hyperproliferation and / or cutaneous inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combating these pathologies.
Owner:NAOS INST OF LIFE SCI +1

Application of USP7 as target spot in preparation of medicine for treating abnormal vascular leakage diseases

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.
Owner:NANTONG UNIV

Early focus multi-mode imaging observation endoscope system

The invention provides an early-stage focus multi-mode imaging observation endoscope system, and belongs to the technical field of medical apparatuses and instruments. An integrated electronic endoscope; the integrated electronic endoscope internally comprises an image processing device, an ultrasonic processor, a display, a natural light source device and a composite optical fiber, the system can quickly switch a white light mode and a narrow-band light mode, and tiny blood vessel abnormalities on the mucous membrane surface layer can be clearly shown; when a suspicious area is found, ultrasonic and opto-acoustic synchronous imaging can be started instantly, and the deep infiltration condition and metabolic activity information of a focus are obtained noninvasively; when pathology-level confirmation is needed, a multi-mode cooperative working mechanism of confocal microscopic imaging, in-vivo optical biopsy and direct observation of cellular morphology and glandular canal structures can be started, so that focuses, such as early cancerization and precancerous lesions, which are easy to be missed in diagnosis by a traditional endoscope can be found and identified earlier and more accurately, and the missed diagnosis rate and the misdiagnosis rate are remarkably reduced.
Owner:BEIJING CHUNLIZHENGDA MEDICAL INSTR

Assembly and method for the closure of vascular abnormalities

ActiveUS12667351B2Vascular malformationBiomedical engineering
Described herein is a patch delivery assembly for treating a target site and a method for deploying the same. The patch delivery assembly includes a patch installation frame having a self-expanding body extending between a proximal end and an open distal end and defining a lumen therethrough. The patch delivery assembly also includes a delivery cable having a distal end coupled to the proximal end of the patch installation frame and further defining the lumen, and a securement device extending through the lumen defined through the delivery cable and the patch installation frame, the securement device terminating in a distal working end including a securement mechanism. In a deployment configuration of the patch delivery assembly, the patch delivery assembly further includes a patch releasably coupled to the distal end of the patch installation frame, for securement to tissue of the target site using the securement mechanism.
Owner:ST JUDE MEDICAL CARDILOGY DIV INC

Combined tbs stroke motor aphasia abnormality assessment system

This invention relates to the field of healthcare technology, specifically to a stroke motor aphasia abnormality assessment system combined with TBS (Traumatic Brain Spectroscopy). The system includes a vascular abnormality analysis module, a point set acquisition module, a mismatch analysis module, and an operational adjustment module. The system generates microvascular abnormality indicators by detecting the concentrations of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF); simultaneously extracts EEG frequency band energy and near-infrared oxyhemoglobin concentration, and obtains neural excitation point sets and blood flow response point sets through maximum search; based on the microvascular abnormality indicators, it amplifies the blood flow response amplitude and performs spatiotemporal weighted matching on the two types of point sets to obtain the degree of mismatch reflecting the true supply and demand relationship; furthermore, it calculates the cumulative abnormality coefficient by combining the multi-cycle mismatch degree to achieve TBS operational adjustment. This scheme overcomes the shortcomings of traditional methods that rely on strict signal alignment, effectively distinguishes between physiological time drift and decoupling, and improves the robustness of TBS operation.
Owner:HUBEI INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL (HUBEI OCCUPATIONAL DISEASE HOSPITAL)

Bispecific antibody specifically binding to tie2 and VEGF, and use thereof

The present invention provides a novel anti-Tie2 antibody or fragment thereof, and a bispecific antibody comprising the antibody and a VEGF-specific binding site. The anti-Tie2 antibody according to the present invention induced phosphorylation by specifically binding to the Tie2 protein. At this time, the antigen specificity and affinity of the anti-Tie2 antibody were excellent compared to existing ligands (Ang-1, Ang-2). In addition, the bispecific antibody comprising the anti-Tie2 antibody and the VEGF binding site inhibited VEGF while activating the Tie2 protein. In particular, the bispecific antibody effectively inhibited side effects that can be caused by an inhibitor of VEGF. In addition, the anti-Tie2 antibody or bispecific antibody exhibited a therapeutic effect on diseases in a mouse model of vascular abnormality-related diseases. Thus, the anti-Tie2 antibody and the bispecific antibody comprising the anti-Tie2 antibody and the VEGF-specific binding site according to the present invention can be used as a therapeutic agent for vascular abnormality-related diseases.
Owner:MABTICS CO LTD

A Rapamycin method of treatment and composition

PendingGB2644518A8Organic active ingredientsAerosol deliveryRapamycin treatmentHuman skin
The invention includes a method for treating a vascular abnormality of the skin of a human subject, comprising topically administering to the abnormality a composition comprising: a) Rapamycin; b) Monolaurin and Monomyristin as vehicle; and c) water; once daily at a rate of: d) 4 -8 mg Rapamycin / cm2; and / or e) 1-6 mg Rapamycin.
Owner:AFT PHARM LTD

Application of Sivelestat in preparation of cancer radiotherapy adjuvant drugs

The invention belongs to the field of new application of medicines, and particularly relates to application of Sivelestat in preparation of cancer radiotherapy adjuvant medicines. According to the invention, Sivelestat which has been used for acute respiratory distress syndrome is creatively applied to tumor radiotherapy, and the Sivelestat inhibits the activity of neutrophil elastase and effectively blocks the formation of a neutrophil outer trapping net induced by radiotherapy, so that the invasion of tumor cells and the abnormal generation of blood vessels are inhibited, and an immunosuppression microenvironment is established. The application not only maintains the local killing effect of radiotherapy on primary tumors, but also cuts off the key path from radiotherapy to NETs to metastasis from the mechanism, and significantly reduces the risk of tumor recurrence and distant metastasis after radiotherapy. The traditional Chinese medicine composition has the transformation advantage of new use of old medicines, is clear in clinical safety, and is suitable for adjuvant therapy of various solid tumors.
Owner:XI AN JIAOTONG UNIV

An intraaortic balloon counterpulsation catheter

ActiveCN120437483BBalloon catheterBlood pumpsLeft subclavian arteryFemoral artery
The present invention discloses an aortic balloon counterpulsation catheter, which relates to the technical field of medical devices. The present invention comprises a cuff, wherein a guide wire tube 1, an airway tube 1 and a blood pressure tube 1 are arranged inside the cuff, an outer tube is fixedly connected to the left end of the cuff, and the outer tube adopts a three-cavity structure design, which is respectively connected to the guide wire tube 1, the airway tube 1 and the blood pressure tube 1, and a pressure measuring hole is opened on the outer side of the outer tube, which is connected to the blood pressure tube 1. The present invention has a pressure measuring hole on the opposite side of the tip side of the balloon, that is, a pressure measuring hole is arranged on the outer tube, and then the pressure measuring passage is realized by the three-cavity structure design of the outer tube part, and is extended by the blood pressure tube 1 to be connected to the pressure detection equipment. This design can realize the aortic balloon counterpulsation catheter as a catheter to intervene in the aorta through the subclavian artery or the carotid artery, solving the problem that the aortic balloon counterpulsation catheter cannot be placed due to femoral artery vascular abnormalities in clinical practice.
Owner:ANJI TAIXIN (TIANJIN) HEALTH IND CO LTD +1

Systems and methods for visualizing computed tomography angiography images

Embodiments herein rapidly transform computed tomography angiography (CTA) data into an interactive, holographic visualization for clinical use. In one embodiment, a system for visualizing computed tomography angiography (CTA) images comprises a data interface configured to receive CTA image data in a Digital Imaging and Communications in Medicine (DICOM) format. The system also comprises a processor configured to render a plurality of two-dimensional CTA slice images into a three-dimensional (3D) volumetric dataset from the CTA image data, to filter the 3D volumetric dataset to resolve vascular structures relative to surrounding tissue and bone, and to generate an extended reality (XR) holographic representation of the filtered 3D volumetric dataset. The system also comprises an XR display device configured to present the holographic representation to a user for the user to manipulate the holographic representation and identify a vascular abnormality.
Owner:RGT UNIV OF CALIFORNIA

Automatic detection system for intracranial aneurysm based on CT image

This invention relates to the field of image processing technology, specifically to an automated intracranial aneurysm detection system based on CT images. The system includes: analyzing all local regions of each vascular segment based on vascular CT images to obtain the probability of local vascular abnormalities; identifying potential abnormal bulging regions based on these probabilities; further obtaining candidate regions for the vascular segment and candidate regions for bifurcation points; obtaining a first aneurysm probability based on the degree of protrusion and perpendicularity of the growth direction of the candidate regions, and distinguishing between physiological curvature and aneurysm regions based on the first aneurysm probability; calculating a second aneurysm probability based on the positional difference value and sphericity matching degree of the candidate regions for bifurcation points, and distinguishing between natural bulges at bifurcation points and aneurysm regions based on the second aneurysm probability. By analyzing different morphologies and structures of intracranial vessels, the system distinguishes between normal vascular structures and aneurysm regions, thereby achieving accurate identification of intracranial aneurysms.
Owner:XIAN THIRD HOSPITAL

Physics informed neural network for assessing hemodynamics

PCT designated stageWO2026136838A1Medical simulationPattern recognitionData set
Systems and methods utilizing neural networks and associated architecture for assessing blood flow and vascular anomalies are disclosed herein. Systems and methods may assess blood flow and / or predict vascular anomalies by deriving point cloud data from angiographic data to form three-dimensional (3D) datasets, and may further input derived data into a neural network such that the neural network outputs and provides visual results in a 3D space and / or map displaying one or more of velocity streamlines, pressure contours and shear stress distributions representative of a patient or subject vasculature.
Owner:ANGIOINSIGHT INC

Ai-assisted detection of vascular anomalies in medical images

A computer-implemented training data preparation method comprises: receiving an input medical image of vessels of a patient; determining a vessel segmentation from the input medical image; identifying and annotating anatomical landmarks in the vessel segmentation to produce an annotated vessel segmentation; and storing the annotated vessel segmentation as training data. A training method for training neural networks based on the training data and a medical diagnostic method applying trained AI models are also provided.
Owner:SIEMENS HEALTHINEERS AG +1

Devices for treating vascular abnormalities

A device for treating aneurysms and a delivery method are described, comprising a permeable shell having an open distal end, an internal compressible mesh structure having a lumen, and an external constraint surrounding at least a portion of the internal compressible mesh structure. The external constraint may have variable stiffness. The deployed configuration of the permeable shell may be torus-shaped, with the internal compressible mesh structure disposed along the longitudinal axis of the permeable shell. The external constraint may be a coil or a hypotube. The external constraint may have a proximal portion that is stiffer than the distal portion. The stiffer proximal portion of the external constraint may attenuate hemodynamic forces at the proximal end of the permeable shell.
Owner:MICROVENTION INC

Devices and methods for the treatment of vascular abnormalities

Described herein is a medical device for treating a target site. The medical device includes a proximal end including a disc and a distal end including a lobe. The disc and lobe are connected by a connecting member. The disc includes a proximal surface, a distal surface, and a central surface extending between and connecting the proximal surface and distal surface, wherein the central surface separates the proximal surface from the distal surface by a predetermined depth distance.
Owner:ST JUDE MEDICAL CARDILOGY DIV INC

Pulmonary artery embolism guiding method and system based on chest CT (Computed Tomography) plain-scan image

The invention provides a pulmonary artery embolism guiding method and system based on a chest CT plain-scan image, and the method comprises the steps: obtaining the chest CT plain-scan image of a patient, and generating continuous pulmonary artery image data through an image motion compensation strategy; shape distribution information and blood density distribution information of all blood vessels of the pulmonary artery are captured through an image recognition model so as to recognize the blood vessel abnormal range and the blood vessel abnormal degree of all embolism blood vessels, and the pulmonary artery embolism probability of the patient is obtained based on the blood vessel abnormal range and the blood vessel abnormal degree of all the embolism blood vessels. And generating a pulmonary artery embolism guidance report of the patient. By adopting the scheme, the accuracy of guiding the medical staff to identify the pulmonary artery embolism of the patient can be improved.
Owner:EDONG MEDICAL GRP CENT HOSPITAL (CITY PUAI HOSPITAL AFFILIATED HOSPITAL OF HUBEI INST OF TECH)

Intravascular device with expandable filter and sheath

PendingCN121666215AMulti-lumen catheterHeart valvesEndovascular treatmentEndovascular therapy
The invention provides a catheter with a filter. The catheter is configured for use in the treatment of vascular abnormalities. The filter element is configured to capture emboli within a patient's blood vessel and is expandable from a collapsed configuration, and may have a stretchable proximal portion to accommodate insertion of an intravascular treatment device. The catheter is configured for radial expansion to facilitate insertion of an endovascular treatment device into the catheter lumen, whereby the catheter is reconfigured from a normal configuration in which the main lumen defines a first size to an expanded configuration in which the main lumen defines a second size. The main lumen defines a second dimension greater than the first dimension.
Owner:丹尼尔·以斯拉·沃尔兹曼

Rapamycin composition and treatment method

The present invention comprises a method of treating skin vascular abnormalities in a human subject comprising topically applying to an abnormal site a composition comprising: a) rapamycin; b) glycerol monolaurate and glycerol monomyristate which are used as carriers; and c) water; the dosage is as follows: d) 4 to 8 mg of rapamycin per square centimeter; and / or e) from 1 mg to 6 mg of rapamycin.
Owner:AFT PHARM LTD

A Rapamycin method of treatment and composition

PendingGB2644518AOrganic active ingredientsAerosol deliveryRapamycin treatmentGlycerol
The invention includes a method for treating a vascular abnormality of the skin of a human subject, comprising topically administering to the abnormality a composition comprising: a) Rapamycin; b) Monolaurin and Monomyristin as vehicle; and c) water; once daily at a rate of: d) 4 -8 mg Rapamycin / cm2; and / or e) 1-6 mg Rapamycin.
Owner:AFT PHARM LTD